Efficacy and Safety of Org 25969 Administered After Zemuron® (MK-8616-042)
Status:
Completed
Trial end date:
2005-05-26
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to explore the dose-response relation of MK-8616 (Org
25969) given as a reversal agent of Zemuron® at 1 to 2 post tetanic counts (PTCs); both
Zemuron® and MK-8616 are administered by intravenous (iv) infusion. Another goal of the study
is to evaluate the safety of single doses of MK-8616 administered to participants of American
Society of Anesthesiologists (ASA) Physical Status Class 1 (otherwise normal, healthy
participant); Class 2 (participant with a mild systemic disease); or Class 3 (participant
with a severe systemic disease that limits activity, but is not incapacitating).